Newsletters & Publications

The SPIRO-CKD trial has now closed.  A summary of the trial’s findings will be provided in due course.
Thank you to all of our collaborators for helping us to successfully deliver this important trial.

Publications:

Hayer MK, Edwards NC, Slinn G, Moody WE, Steeds RP, Ferro CJ, et al. A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial. Am Heart J. 2017;191:37-46.